The FDA on April 23, 2024, approved LUTATHERA® for pediatric patients 12 years and older with Somatostatin Receptor (SSTR)-positive GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors. LUTATHERA® received approval for this indication for adults in 2018. LUTATHERA® is a product of Advanced Accelerator Applications USA, Inc., a Novartis company.
Bottom Ad
Advertisement
Subscribe
